How aging and sex reshape the immune system’s fight against cancer

The immune system does not age uniformly, and neither does it age identically in men and women. A new study published in Nature Aging by researchers at the Mass General Brigham Cancer Institute reveals that the timing and character of immune decline differ sharply between biological sexes, and that these differences may help explain why cancer immunity and responses to immunotherapy vary so widely between patients. The work, led by first author Lutz Menzel, PhD, formerly of the Department of Radiation Oncology, and senior author Tim Padera, PhD, combines detailed mouse experiments with human imaging and immune-cell datasets to trace a mechanistic chain that runs from the thymus, through the lymph nodes, all the way to the ability of T cells to recognize tumor cells. The findings arrive at a moment when clinicians increasingly recognize that a patient’s age and sex are not incidental variables in cancer care but active shapers of treatment outcomes.

The central problem the researchers set out to address is one of the most persistent puzzles in immunology: why does the capacity to mount new immune responses fade with age? Immune checkpoint blockade, one of the most transformative advances in modern oncology, depends entirely on the immune system’s ability to recognize tumor antigens and respond to them. When that recognition machinery weakens, immunotherapies lose much of their power. Yet the biological reasons for this decline have remained incompletely understood. Complicating the picture further, biological women and men show substantial differences in cancer incidence, immune function, and responses to immunotherapy, but how biological sex interacts with the aging process itself has been largely unexplored at the mechanistic level.

To dissect this question, the team built a multi-layered experimental strategy. In female and male mice, they tracked changes across the lifespan in three key components of anti-cancer immunity: the lymph nodes, the thymus, and the population of naive CD8 T cells. The thymus is the organ where T cells develop and mature before being released into circulation, while naive CD8 T cells are newly formed cytotoxic lymphocytes that have not yet encountered a threat and stand ready to recognize novel antigens, including those displayed by tumor cells. The researchers then tested how age- and sex-related changes in these components affected the recognition and control of melanoma cells in experimental models. Crucially, they complemented the mouse work with human imaging and immune-cell datasets to determine whether the same patterns hold in people.

The results revealed a striking sex-biased divergence in how the immune system ages. In male mice, naive CD8 T cells were lost earlier in life than in females, and this loss was accompanied by an earlier contraction of lymph node size. Lymph nodes are the anatomical staging grounds where T cells survey antigen-presenting cells, so their shrinkage has direct functional consequences: fewer naive T cells were locally available to scan for tumor antigens, and the anti-cancer immune responses that depend on that surveillance were correspondingly impaired. In other words, the study links a structural change, the physical contraction of lymph nodes, to a cellular change, the depletion of naive CD8 T cells, and finally to a clinical consequence, compromised antigen recognition during middle age.

Perhaps the most consequential finding concerns the thymus and its suppression by male sex hormones. When the researchers temporarily reduced the suppressive effects of androgens on the thymus in middle-aged male mice, the organ’s output of new T cells rebounded. This replenished the pool of naive CD8 T cells within the lymph nodes, improved the recognition of tumor cells, and enhanced the response to immune checkpoint blockade. The experiment demonstrates that the age-related decline in anti-cancer immunity is not an irreversible feature of aging but a process that can, at least in principle, be partially reversed by intervening at the right biological node. It also provides a mechanistic explanation for why male mice, and potentially male patients, might show earlier erosion of the immune machinery that immunotherapies rely upon.

The human data lent substantial support to the mouse findings. Differences in lymph node size between the sexes, age-related shrinkage of the thymus, and declines in naive CD8 T cell populations all appeared in human datasets in patterns consistent with the experimental results. This cross-species concordance matters because it suggests the mechanism is not an artifact of laboratory mouse models but a feature of human immune biology. For clinicians, it raises the possibility that measurable indicators of thymic function, lymph node architecture, or naive T cell abundance could eventually serve as biomarkers for assessing a patient’s capacity to generate new anti-cancer immune responses before treatment begins.

The real-world implications extend to individualized treatment decisions. If age and sex shape the immune environment in ways that influence cancer outcomes and immunotherapy responses, then understanding a patient’s immune aging profile could help clinicians predict who is likely to benefit from checkpoint blockade and who might need combination strategies or alternative approaches. Rather than treating all patients with the same immunotherapy expectations, oncologists could one day factor in the state of the thymus and the naive T cell compartment, tailoring interventions to the immune system the patient actually has rather than an assumed average.

The study also contributes to a growing reassessment of the thymus itself. For decades, the prevailing view held that the thymus becomes largely irrelevant after childhood, gradually shrinking into functional obscurity. Recent work from the Scadden Lab and the Artificial Intelligence in Medicine Program at Mass General Brigham has challenged that assumption, showing that thymic health in adults is associated with overall health and with outcomes from cancer immunotherapy. Related findings suggest that protecting the thymus during cancer therapy can improve patient outcomes. The new study adds a mechanistic layer to this emerging picture by demonstrating how continued thymic output helps maintain the pool of naive T cells available in lymph nodes to recognize cancer antigens throughout adulthood.

This reframing carries significant conceptual weight. The adult thymus is no longer viewed simply as an organ in decline but as a potential determinant of immune competence across the lifespan, and, by extension, a target for future strategies aimed at preserving or restoring anti-cancer immunity. The finding that a short period of thymic regeneration in middle-aged mice was sufficient to improve tumor recognition and checkpoint blockade response hints at therapeutic windows that could be exploited clinically, whether through hormonal modulation, thymus-protective measures during cancer treatment, or other approaches that sustain T cell production into later life.

The research, published under the title ‘Lymph node contraction links sex-biased naive CD8 T cell decline to compromised antigen recognition during middle age,’ was supported by the German Research Foundation, the National Institutes of Health, the Heart-Lung Foundation of Sweden, and the Swedish Research Council, with additional support through the MGH Research Scholars Program from the Rullo Family. The authors reported no relevant financial disclosures. As the field moves forward, the study stands as a reminder that the immune system’s relationship with cancer is shaped by biology that begins far upstream of the tumor itself, in the organs and architectures that sustain the body’s capacity to recognize what does not belong. Understanding how that capacity erodes differently in men and women may prove essential to making immunotherapy work for everyone.

Subject of Research: Sex-biased immune aging and thymic function in anti-cancer T cell immunity

Article Title: Research Spotlight: New insights into how age and sex shape cancer immunity

Article References: Research Spotlight: New insights into how age and sex shape cancer immunity. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: cancer immunology, immune aging, thymus, T cells, lymph nodes, immunotherapy, immune checkpoint blockade, sex differences, CD8 T cells, melanoma, Nature Aging, tumor antigen recognition